Elevated, combined serum free light chain levels and increased mortality: a 5-year follow-up, UK study
- 25 August 2012
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 65 (11), 1036-1042
- https://doi.org/10.1136/jclinpath-2012-200910
Abstract
Aims: Abnormal serum free light chain (FLC) ratios are diagnostically important in almost all plasma cell disorders. However, absolute increases in polyclonal FLC levels are often discarded as inconsequential. Here we report an association between increased combined polyclonal FLC (cFLC: FLCκ plus FLCλ) concentrations and mortality.Methods: 723 patients sent for 30 routine haematological assessments were enrolled. Patients with a confirmed monoclonal gammopathy were removed. The remaining 527 patients were followed up for up to 4.5 years. Statistical analysis was performed using SPSS (V.19).Results: During follow-up, there were 99 deaths (18.8%). Kaplan-Meier survival analysis revealed 29% of these deaths occurred within the first 100 days (N=29). Multivariate analysis identified only cFLC >65 mg/l, albumin 2 to be independently associated with mortality within 100 days and 4.5 years with, cFLC having the highest HR of 7.1. A simple risk stratification model based only on albumin and cFLC identified 86% mortality within 100 days and 62% over 4.5 years.Conclusions: Elevated cFLC is significantly associated with increased mortality and with albumin can be used to identify patients at risk of mortality at 4.5 years with high-risk patients detected within 100 days.This publication has 32 references indexed in Scilit:
- Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General PopulationMayo Clinic Proceedings, 2012
- Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemiaBlood, 2011
- Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2011
- Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related LymphomaJournal of Clinical Oncology, 2010
- Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyBlood, 2009
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Immunoglobulin free light chains and solitary plasmacytoma of boneBlood, 2006
- Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2006
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004